289 related articles for article (PubMed ID: 8705996)
21. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
[TBL] [Abstract][Full Text] [Related]
22. p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas.
O'Regan EM; Toner ME; Finn SP; Fan CY; Ring M; Hagmar B; Timon C; Smyth P; Cahill S; Flavin R; Sheils OM; O'Leary JJ
Hum Pathol; 2008 Mar; 39(3):452-8. PubMed ID: 18261630
[TBL] [Abstract][Full Text] [Related]
23. Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin.
Tyler LN; Ai L; Zuo C; Fan CY; Smoller BR
Mod Pathol; 2003 Jul; 16(7):660-4. PubMed ID: 12861061
[TBL] [Abstract][Full Text] [Related]
24. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma.
Maesawa C; Tamura G; Nishizuka S; Ogasawara S; Ishida K; Terashima M; Sakata K; Sato N; Saito K; Satodate R
Cancer Res; 1996 Sep; 56(17):3875-8. PubMed ID: 8752149
[TBL] [Abstract][Full Text] [Related]
25. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
26. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
27. Frequent inactivation of p16INK4a in oral premalignant lesions.
Papadimitrakopoulou V; Izzo J; Lippman SM; Lee JS; Fan YH; Clayman G; Ro JY; Hittelman WN; Lotan R; Hong WK; Mao L
Oncogene; 1997 Apr; 14(15):1799-803. PubMed ID: 9150385
[TBL] [Abstract][Full Text] [Related]
28. Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study.
Zheng Y; Shen H; Sturgis EM; Wang LE; Shete S; Spitz MR; Wei Q
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):640-5. PubMed ID: 12101111
[TBL] [Abstract][Full Text] [Related]
29. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
Fueyo J; Gomez-Manzano C; Bruner JM; Saito Y; Zhang B; Zhang W; Levin VA; Yung WK; Kyritsis AP
Oncogene; 1996 Oct; 13(8):1615-9. PubMed ID: 8895506
[TBL] [Abstract][Full Text] [Related]
30. SH3GL2 and CDKN2A/2B loci are independently altered in early dysplastic lesions of head and neck: correlation with HPV infection and tobacco habit.
Ghosh A; Ghosh S; Maiti GP; Sabbir MG; Alam N; Sikdar N; Roy B; Roychoudhury S; Panda CK
J Pathol; 2009 Feb; 217(3):408-19. PubMed ID: 19023882
[TBL] [Abstract][Full Text] [Related]
31. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.
Liu Q; Yan YX; McClure M; Nakagawa H; Fujimura F; Rustgi AK
Oncogene; 1995 Feb; 10(3):619-22. PubMed ID: 7845688
[TBL] [Abstract][Full Text] [Related]
32. High prevalence of p16 genetic alterations in head and neck tumours.
Miracca EC; Kowalski LP; Nagai MA
Br J Cancer; 1999 Oct; 81(4):677-83. PubMed ID: 10574255
[TBL] [Abstract][Full Text] [Related]
33. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain.
Zhang SJ; Endo S; Ichikawa T; Washiyama K; Kumanishi T
Cancer Res; 1998 Mar; 58(6):1231-7. PubMed ID: 9515810
[TBL] [Abstract][Full Text] [Related]
34. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
35. Deletion of P15 (MTS2) in head and neck squamous cell carcinomas.
Roesler JM; Livingston EH; Srivatsan E; Chang P; Wang MB
J Surg Res; 1998 Jun; 77(1):50-4. PubMed ID: 9698532
[TBL] [Abstract][Full Text] [Related]
36. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
Merbs SL; Sidransky D
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):779-83. PubMed ID: 10067984
[TBL] [Abstract][Full Text] [Related]
37. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
[TBL] [Abstract][Full Text] [Related]
38. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
[TBL] [Abstract][Full Text] [Related]
39. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma.
Yarbrough WG
Laryngoscope; 2002 Dec; 112(12):2114-28. PubMed ID: 12461329
[TBL] [Abstract][Full Text] [Related]
40. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
